Back

Phenotypic impact of sarcomeric versus non-sarcomeric genetic variants in hypertrophic cardiomyopathy: a real-world analysis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Helena Santos Moreira

Sao Joao University Hospital Centre, Porto (Portugal)

6 More presentations in this session

Presentation thumbnail
Time to consider atrial and diastolic function as key drivers of major adverse cardiovascular events in hypertrophic cardiomyopathy
Doctor A. Martins (Leiria, PT)
Abstract
Presentation thumbnail
Clinical and economic burden in NYHA class I versus II-IV hypertrophic cardiomyopathy: real-world survey data from the United States of America
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract
Presentation thumbnail
Differentiating hypertrophy phenocopies from afterload-induced left ventricular hypertrophy using artificial intelligence-enabled electrocardiography
Mr D. Ahmetagic (Utrecht, NL)
Abstract
Presentation thumbnail
Patient characteristics in pediatric hypertrophic cardiomyopathy: insights from an observational study
Mrs X. Pan (Princeton, US)
Abstract
Presentation thumbnail
Impact of guideline-directed medical therapies on clinical and economic outcomes in nonobstructive hypertrophic cardiomyopathy: analysis of data from a multinational cross-sectional survey
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract

Access the full session

Session thumbnail
Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources